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OBJECTIVE—Although the H2
g7 major histocompatibility com-
plex (MHC) provides the primary pathogenic component, the
development of T-cell–mediated autoimmune type 1 diabetes in
NOD mice also requires contributions from other susceptibility
(Idd) genes. Despite sharing the H2
g7 MHC, the closely NOD-
related NOR strain remains type 1 diabetes resistant because of
contributions of protective Idd5.2, Idd9/11, and Idd13 region
alleles. To aid their eventual identiﬁcation, we evaluated cell
types in which non-MHC Idd resistance genes in NOR mice exert
disease-protective effects.
RESEARCH DESIGN AND METHODS—Adoptive transfer
and bone marrow chimerism approaches tested the diabetogenic
activity of CD4 and CD8 T-cells from NOR mice and NOD stocks
congenic for NOR-derived Idd resistance loci. Tetramer staining
and mimotope stimulation tested the frequency and proliferative
capacity of CD4 BDC2.5-like cells. Regulatory T-cells (Tregs)
were identiﬁed by Foxp3 staining and functionally assessed by in
vitro suppression assays.
RESULTS—NOR CD4 T-cells were less diabetogenic than those
from NOD mice. The failure of NOR CD4 T-cells to induce type 1
diabetes was not due to decreased proliferative capacity of
BDC2.5 clonotypic-like cells. The frequency and function of
Tregs in NOD and NOR mice were also equivalent. However,
bone marrow chimerism experiments demonstrated that intrin-
sic factors inhibited the pathogenic activity of NOR CD4 T-cells.
The NOR Idd9/11 resistance region on chromosome 4 was found
to diminish the diabetogenic activity of CD4 but not CD8 T-cells.
CONCLUSIONS—In conclusion, we demonstrated that a
gene(s) within the Idd9/11 region regulates the diabetogenic
activity of CD4 T-cells. Diabetes 57:3273–3280, 2008
I
n both humans and NOD mice, type 1 diabetes
results from T-cell–mediated autoimmune destruc-
tion of insulin-producing pancreatic -cells (1,2).
Both CD4 and CD8 T-cells are essential for type 1
diabetes development in NOD mice (1,3). Similar to the
case in humans, multiple genetic susceptibility (Idd) loci
contribute to type 1 diabetes in NOD mice (1). The H2
g7
major histocompatibility complex (MHC) provides the
primary component of type 1 diabetes susceptibility in
NOD mice, but alone, it is insufﬁcient for disease develop-
ment (1). In conjunction with the H2
g7 MHC, other Idd
genes are also required to interactively contribute to the
development of diabetogenic T-cell responses in NOD
mice (1). Although the identities of some non-MHC Idd
genes have been revealed (4–6), most of them remain
unknown.
A resource allowing inquiry to the function of non-MHC
Idd genes is the NOR mouse (7). NOR mice share 88% of
their genome with the NOD strain, including the H2
g7
MHC (7). However, major disease resistance genetic loci
on chromosomes (Chr) 1 (Idd5.2) ,2( Idd13), and 4
(Idd9/11) completely protect NOR mice from type 1
diabetes (8–10). Ctla-4 most likely represents the Idd5.1
subregion gene, but the susceptibility allele is shared by
NOD and NOR mice (8,10). Conversely, the NOR strain
appears to differ from NOD mice by the presence of a type
1 diabetes–protective Idd5.2 sublocus. Allelic variants of
2-microglobulin (2m) represent one of at least two
polymorphic Idd13 region genes respectively contributing
to type 1 diabetes susceptibility or resistance in NOD or
NOR mice (4). Polymorphic 2m variants induce confor-
mational differences in MHC class I molecules, which
inﬂuences their ability to positively select autoreactive
CD8 T-cells (11). In addition, the pathogenic activity of
NOR B-cells is signiﬁcantly lower than those of NOD origin
because of contributions from Idd9/11 region genes on
Chr4 (12). Type 1 diabetes–protective genetic polymor-
phisms in NOR mice also suppress the pathogenic activity
of T-cells transgenically expressing T-cell receptors
(TCRs) from the diabetogenic CD4 (NY4.1) and CD8
(NY8.3) clones (13). However, further congenic mapping
of NOR genetic variants responsible for the greatly dimin-
ished pathogenic activity of these diabetogenic CD4 and
CD8 T-cell clones has not been reported.
Multiple phenotypic or functional differences in several
immunological components, including T-cells, dendritic
cells, and macrophages, have also been reported between
NOD and NOR mice (14–18). Eventual identiﬁcation of
unknown NOR Idd resistance genes can be aided by
determining the cell types in which they individually or in
combination exert disease protection effects. Thus, in the
current study, we deﬁned the role that speciﬁc NOR-
derived Idd resistance loci may play in limiting the devel-
opment of diabetogenic CD4 and CD8 T-cells.
RESEARCH DESIGN AND METHODS
NOD/ShiLtDvs and closely related NOR/Lt mice (7) are maintained by
brother-sister mating at The Jackson Laboratory (Bar Harbor, ME). Stocks
of NOD background mice carrying NOR-derived congenic intervals on Chr1
NOD.NOR-(D1Mit532-D1Mit8)/DvsJ (here designated NOD.Chr1
NOR) or Chr4
NOD.NOR-(D4Mit31-D4Mit310)/DvsJ (here designated NOD.Chr4
NOR) have
been described previously (10). In the latter of these two stocks, the
NOR-derived Chr4 congenic interval was found to extend more distally than
previously reported (10) to also encompass the marker D4Mit310. The
NOD.NOR-(D2Mit63-D2Mit48)/LtJ congenic stock (here designated
NOD.Chr2
NOR) was termed NOD.D2Mit490-Mit144
NOR in a previous study
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modiﬁed from that originally reported because of updated knowledge of
marker positions. Previously described NOD congenic stocks respectively
deﬁcient in CD4 and CD8 T-cells (designated NOD.CD4
null and NOD.CD8
null)
were also used (19,20). A NOD stock lacking B-cells (21) is now maintained at
the N10 backcross generation (termed NOD.IgH
null). A NOD.IgH
null substock
with B-cells that only express transgene-encoded HEL-speciﬁc Ig molecules
(designated NOD.IgHEL.IgH
null) has been previously reported (21). NOD
mice transgenically expressing the TCR from the diabetogenic CD8 T-cell
clone AI4 (V8/V2) and congenic for a functionally inactivated Rag1 gene
(NOD.Rag1
null.AI4) have also been described previously (22). Female mice
were used for all experiments.
Adoptive transfer of AI4 T-cells. Mice (6–8 weeks old) were sublethally
irradiated (600R from a
137Cs source) and injected intravenously with 5–10 
10
6 NOD.Rag1
null.AI4 splenocytes (equivalent to 1–2  10
6 AI4 T-cells).
Similar results were obtained over this dose range of NOD.Rag1
null.AI4
splenocytes. In some experiments, AI4 T-cells were preactivated in vitro.
Brieﬂy, NOD.Rag1
null.AI4 splenocytes were cultured at 5  10
6 cells/ml with
0.1 mol/l of the previously described antigenic mimotope peptide (YFIE-
NYLEL) (23) and 25 units/ml recombinant human interleukin (IL)-2 for 2 days.
After activation, 1  10
6 viable AI4 T-cells were injected into the recipients.
The comparative activation state of freshly ex vivo–isolated and in vitro
antigen–stimulated AI4 T-cells were compared by ﬂow cytometry using
antibodies speciﬁc for the CD25 (PC61), CD69 (H1.2F3), and CD44 (IM7.8.1)
markers. In each transfer experiment, standard NOD mice and other various
test recipient stocks were compared side by side. Recipient mice were
monitored for type 1 diabetes development over a 2-week period by daily
monitoring of glycosuria onset with Ames Diastrix (Bayer, Diagnostics
Division, Elkhart, NJ).
Generation of mixed bone marrow/T-cell chimeras. NOD.CD4
null mice at
4–7 weeks of age were lethally irradiated (1300R from a
137Cs source) and
reconstituted as previously described (24) with 5  10
6 of the indicated
T-cell–depleted bone marrow cells isolated from 6- to 10-week-old donors. In
some experiments, 5  10
6 T-cell–depleted NOD.CD4
null bone marrow cells
were admixed with 5  10
6 puriﬁed CD4 T-cells as indicated. Splenic CD4
T-cells were puriﬁed from 6- to 9-week-old mice by depleting B220
, CD8
,
and CD11b
 cells with the previously described magnetic bead system (25).
Biotinylated antibodies speciﬁc for B220 (RA3–6B2), CD8 (53–6.7), and
CD11b (M1/70) were obtained from BD Bioscience. The purity of CD4 T-cells
was routinely 92%, as determined by ﬂow cytometry. A similar approach was
used to study the diabetogenic activity of CD8 T-cells using lethally irradiated
NOD.CD8
null mice as recipients. CD8 T-cells were puriﬁed with the same
magnetic bead system by depleting B220
, CD4
 (clone GK1.5, BD Bio-
science), and CD11b
 cells. Type 1 diabetes was again monitored by onset of
glycosuria.
Treg and BDC2.5 effector enumeration. The frequency of CD4 diabeto-
genic BDC2.5-like cells was determined by tetramer staining as previously
described (26) with the exception that the tetramer reagent was used at a
concentration of 4.0 g/ml, and the staining was carried out at 37°C.
Propidium iodide was used to gate out dead cells. Regulatory T-cells (Treg)
were identiﬁed by surface staining with anti-CD4 (clone GK1.5) and intracel-
lular staining with anti-Foxp3 (clone FJK-16s) using an intracellular staining
kit from eBioscience. Stained cells were washed and analyzed on a FACSCali-
bur ﬂow cytometer (Becton Dickinson).
In vitro Treg assay. CD4 T-cells were puriﬁed as described above. The
CD25
 fraction was further isolated by staining with biotinylated anti-CD25
(clone 7D4; BD Bioscience) followed by streptavidin-conjugated microbeads
(Miltenyi Biotec). CD4
CD25
 cells were then enriched by positive selection
using an LS column (Miltenyi Biotec). The CD4
CD25
 fraction was used as
the effector population. Effector cells were labeled with carboxyﬂuorescein
succinimidyl ester (CFSE) as previously described (27). Labeled effector cells
(5  10
4) were cocultured in triplicate with indicated numbers of putative
CD4
CD25
 Tregs in the presence of 2  10
5 NOD.scid splenocytes and 5
g/ml anti-CD3 (clone 145–2C11, BD Bioscience) in round-bottomed 96-well
tissue culture plates in a ﬁnal volume of 200 l culture medium as previously
described (28). Proliferation of effector cells was determined after 3 days of
culture by CFSE dilution.
BDC2.5 mimotope priming and recall assay. NOD, NOR, and
NOD.Chr4
NOR females (8 weeks old) were immunized in a rear footpad with
20 g BDC2.5 mimotope (AHHPIWARMDA) or a control IA
g7 binding peptide
(LSIALHVGFDH) emulsiﬁed in incomplete Freund’s adjuvant (IFA). Ten days
later, 1  10
6 cells from dispersed draining lymph nodes were seeded in
triplicate into ﬂat-bottomed 96-well tissue culture plates in a ﬁnal volume of
200 l culture medium as previously described (28) containing varying
concentrations of BDC2.5 mimotope. Cells were cultured for 3 days and
labeled with 1 Ci/well [
3H]thymidine during the last 20 h. Interferon-	
(IFN-	), IL-4, and IL-10 were analyzed by ELISA kits (BD Bioscience).
RESULTS
Idd9/11-regulated events in CD4 T-cells and B-cells
modulate the diabetogenic activity of AI4 CD8
T-cells. Autoreactive CD8 T-cells are essential to the
initiation of type 1 diabetes development in NOD mice
(29,30), but their efﬁcient activation requires contributions
from other immunological components. Thus, it seemed
possible that some gene(s) contributing to type 1 diabetes
resistance in the closely NOD-related NOR strain could do
so by limiting the ability of other immunological compo-
nent(s) to provide functions necessary for the efﬁcient
activation of pathogenic CD8 T-cells. CD8 T-cells trans-
genically expressing the AI4 TCR rapidly induce type 1
diabetes when adoptively transferred into sublethally irra-
diated standard NOD recipients (27). Therefore, we asked
whether the AI4 adoptive transfer method could also
induce type 1 diabetes in NOR mice or NOD stocks
congenic for NOR-derived chromosomal regions carrying
protective alleles. Although 75% of standard NOD mice
receiving NOD.Rag1
null.AI4 splenocytes developed type 1
diabetes within 2 weeks, all of the NOR recipients
remained disease free over the same period of time
(Table 1). Both NOD.Chr1
NOR and NOD.Chr2
NOR con-
genic strains were susceptible to AI4 T-cell–induced
type 1 diabetes (Table 1). In contrast, no NOD.Chr4
NOR
recipients developed type 1 diabetes under the same
transfer conditions (Table 1).
We next asked what particular host lymphocyte popu-
lations modulate the diabetogenic activity of adoptively
transferred AI4 T-cells. To do this, we transferred
NOD.Rag1
null.AI4 splenocytes into sublethally irradiated
NOD mice lacking B cells (NOD.IgH
null), CD8 T-cells
(NOD.CD8
null), or CD4 T-cells (NOD.CD4
null). Both host
B-cells and CD4 T-cells, but not CD8 T-cells, were impor-
tant for adoptively transferred AI4 T-cells to mediate type
1 diabetes development (Table 1). One important role of
autoreactive B-cells for type 1 diabetes development in
NOD mice is to function as a preferential antigen-present-
ing cell (APC) subset because of a unique ability to
efﬁciently uptake autoantigens through cell surface Ig
molecules (21). This allows these B-cells to subsequently
preferentially present MHC class II–bound self-peptides to
autoreactive CD4 T-cells. However, B-cells may also con-
tribute to autoimmunity by mechanisms independent of
membrane-bound or secreted Ig molecules (31). Further-
more, B-cells also reportedly exert functions facilitating
the ability of dendritic cells to cross-present MHC class
I–bound antigens to CD8 T-cells (32). To test these possi-
bilities, we transferred NOD.Rag1
null.AI4 splenocytes into
sublethally irradiated NOD.IgHEL.IgH
null mice in which
all B-cells express Ig molecules speciﬁc for the disease-
irrelevant HEL protein. Similar to standard NOD recipi-
ents, NOD.IgHEL.IgH
null mice were highly susceptible to
AI4 T-cell–mediated type 1 diabetes (Table 1). Therefore,
antigen speciﬁcity of B-cells was not essential for their
ability to facilitate the pathogenic function of AI4 T-cells.
The majority of directly ex vivo–isolated splenic AI4
T-cells in the transfer inoculums displayed a naive pheno-
type (99% CD69
/CD25
/CD44
low). Therefore, host CD4
T-cells and B-cells appear to facilitate the subsequent
activation of adoptively transferred AI4 T-cells. AI4 T-cells
can independently induce type 1 diabetes in T-cell– and
B-cell–deﬁcient NOD-scid recipients (33) but with signiﬁ-
cantly slower kinetics than observed in the present system
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thally irradiated standard NOD recipients.
We next asked whether AI4 T-cells preactivated in vitro
by mimotope peptide stimulation could induce type 1
diabetes in the absence of host CD4 T-cells or B-cells.
Preactivated AI4 T-cells (66% CD25
CD69
CD44
hi)i n -
duced type 1 diabetes development in CD4 T-cell– or
B-cell–deﬁcient NOD recipients (Table 1). In addition,
NOR and NOD.Chr4
NOR mice rapidly developed type 1
diabetes when receiving preactivated AI4 T-cells (Table 1).
Together, these results indicate that in this adoptive
transfer system, CD4 T-cells and B-cells in NOD mice, but
not NOR or NOD.Chr4
NOR mice, facilitate the pathogenic
activation of AI4 CD8 T-cells. In the current study, we
continued to analyze the mechanism by which Idd9/11
genes regulate the activity of diabetogenic CD4 T-cells.
The role of B-cells in regulating autoreactive CD8 T-cells
will be the subject of future studies.
Reduced pathogenic activity of NOR CD4 T-cells. We
next tested whether mature NOR CD4 T-cells remained
unable to facilitate the initiation of type 1 diabetes devel-
opment when all other components of the immune re-
sponse were of NOD origin. The system used was to
reconstitute lethally irradiated normally type 1 diabetes–
resistant NOD.CD4
null mice (19) with syngeneic bone
marrow mixed with puriﬁed CD4 T-cells from either NOD
or NOR donors. NOD.CD4
null mice receiving syngeneic
bone marrow alone did not develop type 1 diabetes (data
not shown). Of the NOD.CD4
null recipients, 90% devel-
oped type 1 diabetes when reconstituted with syngeneic
bone marrow and NOD CD4 T-cells (Fig. 1A). In contrast,
NOD.CD4
null mice injected with syngeneic bone marrow,
and NOR CD4 T-cells were highly resistant to type 1
diabetes development. NOR B-cells exert signiﬁcantly less
diabetogenic APC activity than those from NOD mice (12).
Therefore, the variable capacity of transferred CD4 T-cells
from NOD and NOR mice to facilitate type 1 diabetes
development could solely result from differences in previ-
ous engagements with antigen-presenting B-cells capable
of expanding pathogenic effectors. If this were the case,
then compared with those of NOD or NOR origin, CD4
T-cells isolated from NOD.IgH
null mice should exhibit
poor diabetogenic activity. Therefore, we reconstituted
NOD.CD4
null mice with syngeneic bone marrow and
CD4 T-cells from NOD.IgH
null mice. CD4 T-cells from
NOD.IgH
null donors were as diabetogenic as those of NOD
origin (Fig. 1A).
MHC class II A
g7 tetramers were used to determine the
frequency of BDC2.5-like diabetogenic CD4 T-cells in the
spleens of NOR mice. Consistent with a previous report
(26), comparable levels of BDC2.5-like CD4 T-cells devel-
oped in NOD and NOR mice (Fig. 1B). However, compared
with both the NOD and NOR strains, BDC2.5-like T-cell
levels are lower in the NOD.IgH
null stock, indicating that
expansion and/or survival of these diabetogenic effectors
is dependent on the presence of B-cells. The proliferation
potential of BDC2.5-like cells in NOR mice was tested
using a priming-recall assay. BDC2.5-like cells from NOD
and NOR mice proliferated similarly in response to peptide
stimulation (Fig. 1C). These collective results indicate that
the inability of NOR CD4 T-cells to support type 1 diabetes
development was not due to diminished numbers of
potential -cell autoreactive effectors.
Intrinsic factors inhibit the development of diabeto-
genic NOR CD4 T-cells. Although NOR CD4 T-cells have
very limited diabetogenic activity, it was not known
whether this is controlled intrinsically or modulated by
functional differences in other cell types. One possible
mechanism downregulating the diabetogenic activity of
CD4 T-cells in NOR mice relative to the NOD strain is they
TABLE 1
Genetic control of susceptibility to AI4 T-cell–induced type 1 diabetes*
Experiment
group Transferred cells Recipients Diabetic P value†
1 NOD.Rag
null.AI4 splenocytes NOD 76.9 (13)
NOR 0 (11) 
0.001
2 NOD.Rag
null.AI4 splenocytes NOD 60 (10)
NOD.Chr1
NOR 30 (10) 0.05
3 NOD.Rag
null.AI4 splenocytes NOD 57.1 (7)
NOD.Chr2
NOR 42.8 (7) 0.05
4 NOD.Rag
null.AI4 splenocytes NOD 70 (10)
NOD.Chr4
NOR 0 (10) 
0.005
5 NOD.Rag
null.AI4 splenocytes NOD 75 (12)
NOD.CD4
null 0 (10) 
0.005
6 NOD.Rag
null.AI4 splenocytes NOD 75 (8)
NOD.CD8
null 33.3 (9) 0.05
7 NOD.Rag
null.AI4 splenocytes NOD 61.5 (13)
NOD.IgH
null 0 (13) 
0.001
8 NOD.Rag
null.AI4 splenocytes NOD 60 (10)
NOD.IgHEL.IgH
null 70 (10) 0.05
9 Activated AI4 T-cells NOD 100 (3)
NOR 100 (3) —
10 Activated AI4 T-cells NOD 100 (4)
NOD.Chr4
NOR 100 (5) —
NOD.CD4
null 100 (5) —
11 Activated AI4 T-cells NOD 100 (5)
NOD.IgH
null 100 (5) —
Data are percent (n). *NOD.Rag
null.AI4 splenocytes or in vitro–activated AI4 T-cells were transferred into 600R irradiated female recipients.
Type 1 diabetes was monitored for a period of 2 weeks. Mice within each experimental group received the same preparation of AI4 T-cells.
†Statistical analysis by 
2 test (vs. NOD recipients in the same experimental group).
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Tregs. In the experiments described above, the splenic
NOR-derived CD4 T-cells transferred to NOD.CD4
null re-
cipients may have also included Tregs. Therefore, we
compared the frequency of splenic Tregs in NOD and NOR
mice based on coexpression of CD4 and Foxp3. NOD and
NOR mice did not differ in percentages of CD4 T-cells that
coexpressed Foxp3 (Fig. 2A and B). In addition, the
percentages of Foxp3
 CD4 T-cells that coexpressed CD25
were similar in these two strains (Fig. 2C). Although
numerically similar, it was possible that Tregs in NOD and
NOR mice functionally differed. However, when tested in
vitro, NOD and NOR CD4
CD25
 Tregs (both 80%
Foxp3
) exhibited similar levels of suppressive activity
(Fig. 3).
We next asked whether NOR CD4 T-cells support type 1
diabetes development when they differentiate from stem
cells in an environment where most cells are NOD derived.
Lethally irradiated NOD.CD4
null mice were reconstituted
with a 4:1 mixture of syngeneic and NOR bone marrow
cells. In this case, all CD4 T-cells were NOR derived with
most other hematopoietic cells and all nonhematopoietic
cells of NOD origin. Control chimeras consisted of
NOD.CD4
null recipients repopulated with a 4:1 mixture of
syngeneic and standard NOD bone marrow cells. These
control chimeras developed a high incidence of type 1
diabetes (Fig. 4). In contrast, recipients of NOD.CD4
null
and NOR bone marrow were completely type 1 diabetes
resistant. NOR-derived leukocytes other than CD4 T-cells
might have actively suppressed type 1 diabetes develop-
ment in these bone marrow chimeras. To test this possi-
bility, another set of control chimeras was reconstituted
with a 4:1 mixture of NOD and NOR bone marrow. Similar
to the recipients of NOD.CD4
null and NOD bone marrow,
the second control group was type 1 diabetes susceptible
(Fig. 4). These collective results indicate that an intrinsic
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FIG. 1. Reduced diabetogenic activity of NOR CD4 T-cells. A: Incidence
of type 1 diabetes in CD4 T-cell–reconstituted NOD.CD4
null mice.
Lethally irradiated 4- to 7-week-old NOD.CD4
null mice were injected
with equal numbers (5  10
6) of syngeneic bone marrow and puriﬁed
CD4 T-cells from NOD, NOR, or NOD.IgH
null donors. Type 1 diabetes
development was then followed for 20 weeks. *P < 0.001, signiﬁcantly
different from NOD CD4 T-cell recipients (Kaplan-Meier log-rank
analysis). B: The frequency of BDC2.5-like diabetogenic CD4 T-cells in
NOD, NOR, or NOD.IgH
null mice. Splenocytes from 6- to 9-week-old
females were stained with CD4 antibodies and BDC2.5 MHC class II
tetramers to identify BDC2.5-like cells. Each symbol represents an
individual mouse. Horizontal bars indicate the means. The percentages
of BDC2.5-like cells did not differ in NOD and NOR mice but were both
signiﬁcantly greater than in the NOD.IgH
null strain (Wilcoxon’s rank-
sum test). C: Functional analysis of BDC2.5-like cells in NOD and NOR
mice. Groups of three mice were primed with 20 g BDC2.5 mimotope
or IA
g7-binding control peptide in IFA. After 10 days, cells from the
draining lymph nodes of the same group were pooled, and all were
restimulated in triplicate with indicated concentration of the BDC2.5
mimotope. The cultures were pulsed with [
3H]thymidine over the ﬁnal
20 h of a 72-h incubation period. Results indicate the mean counts per
minute (CPM)  SE of the triplicates.
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FIG. 2. Comparison of Treg frequencies in NOD and NOR mice.
Splenocytes from 6- to 9-week-old mice were stained with antibodies
against CD4, Foxp3, and CD25 to identify Tregs. A: Representative
plots show the proportion of Foxp3-expressing CD4 T-cells. B: The
percentages of CD4 T-cells expressing Foxp3. C: The percentages of
CD25
 cells among Foxp3
 CD4 T-cells. Each symbol represents an
individual mouse. Horizontal bars indicate the means. There is no
statistically signiﬁcant difference in the percentages shown in B and C
between NOD and NOR mice (Wilcoxon’s rank-sum test).
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diabetogenic responses.
Idd9/11 diabetes resistance loci control the patho-
genic activity of CD4 T-cells. To dissect the genetic
basis of diabetogenic CD4 T-cell development, we recon-
stituted lethally irradiated NOD.CD4
null mice with synge-
neic bone marrow and CD4 T-cells isolated from
NOD.Chr1
NOR, NOD.Chr2
NOR, or NOD.Chr4
NOR mice.
Compared with those of NOD origin, CD4 T-cells isolated
from NOD.Chr4
NOR mice, but not NOD.Chr1
NOR mice,
demonstrated a reduced ability to support type 1 diabetes
development (Fig. 5). There was a possible trend for CD4
T-cells from NOD.Chr2
NOR mice to exert less diabetogenic
activity than those of NOD origin, but this difference did
not achieve statistical signiﬁcance in the number of recip-
ients analyzed (16–18 per group). Using the same bone
marrow chimerism approach described in Fig. 4, we found
that an intrinsic factor(s) limits the pathogenic potential of
NOD.Chr4
NOR CD4 T-cells (data not shown).
We analyzed the function of BDC2.5-like CD4 T-cells in
NOD.Chr4
NOR mice using the same priming-recall assay
described in Fig. 1C. BDC2.5-like CD4 T-cells from NOD
and NOD.Chr4
NOR mice proliferated equivalently (data not
shown). Production of IFN-	, IL-4, and IL-10 by primed
BDC2.5-like cells after antigenic peptide (10 mol/l) re-
stimulation was also assessed. NOD.Chr4
NOR BDC2.5-like
cells produced less IFN-	 than those of NOD origin (58.0 
7.1 and 109.3  3.7 g/ml, respectively). Therefore, the
lower diabetogenic activity of NOD.Chr4
NOR than NOD
CD4 T-cells could result from reduced production of the
inﬂammatory cytokine IFN-	. However, on antigenic stim-
ulation, lower levels of the immunosuppressive cytokine
IL-10 were secreted by BDC2.5-like CD4 T-cells from
NOD.Chr4
NOR than NOD mice (755.9  22.9 and 1,061.3 
38.1 pg/ml, respectively). Hence, Idd9/11 region genes do
not contribute to type 1 diabetes resistance in NOR mice
through enhancing IL-10 production by CD4 T-cells. Both
strains produced undetectable amounts of IL-4. These
results indicated that BDC2.5-like CD4 T-cells in NOD and
NOD.Chr4
NOR mice have the same proliferative capacity
but qualitatively differ in their effector responses.
Common pathways may contribute to the development
of both autoreactive CD4 and CD8 T-cells. Hence, we
assessed whether NOD.Chr4
NOR CD8 T-cells are also less
diabetogenic than those from NOD mice. Interestingly, the
NOR-derived Chr4 congenic interval that inhibited diabe-
togenic CD4 T-cell responses did not diminish the patho-
genic activity of CD8 effectors (Fig. 6). These results
indicate an Idd9/11 region gene(s) distinguishing NOD and
NOR mice selectively controls the pathogenic activity of
CD4 T-cells.
DISCUSSION
Studies using the 4.1 TCR transgenic system found thymic
or peripheral deletion as well as anergy and ignorance do
not contribute to CD4 T-cell tolerance induction in NOR
mice (13). Similarly, we found the frequency and prolifer-
ative capacity of BDC2.5-like CD4 T-cells was comparable
in NOD and NOR mice. The fact that NOR CD4 T-cells
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FIG. 3. Comparison of in vitro suppressive activities of NOD and NOR
Tregs. Effector T-cells (CD4
CD25
) were labeled with CFSE and
cocultured at indicated ratios with Tregs (CD4
CD25
) in triplicate in
a 96-well plate in the presence of NOD.scid splenocytes (2  10
5) and
5 g/ml anti-CD3 for 3 days. Proliferation of effector T-cells was
determined by CFSE dilution. The percentage of suppression is deﬁned
by the percent reduction in the proportion of divided effector T-cells
relative to that of the control without Tregs. Results indicate the
means  SE of the triplicates. Similar results were observed in another
two experiments.
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FIG. 4. Intrinsic factors control the diabetogenic activity of NOR CD4
T-cells. Lethally irradiated NOD.CD4
null mice were reconstituted with
a mixture of syngeneic bone marrow with NOD or NOR bone marrow at
a 4:1 ratio. A control group was reconstituted with a 4:1 mixture of
NOD and NOR bone marrow. Type 1 diabetes development was then
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FIG. 5. The diabetogenic activity of CD4 T-cells is regulated by a
gene(s) within the Idd9/Idd11 region. CD4 T-cells (5  10
6) puriﬁed
from NOD.Chr1
NOR, NOD.Chr2
NOR, or NOD.Chr4
NOR mice and
NOD.CD4
null bone marrow cells (5  10
6) were mixed and injected into
lethally irradiated 4- to 7-week-old NOD.CD4
null recipients. Type 1
diabetes development was then followed weekly for 20 weeks. The
same accumulated incidence of NOD CD4 T-cell recipients shown in
Fig. 1A was also plotted here for comparative purposes. All CD4 T-cell
transfer experiments, including those shown in Fig. 1A, were done in an
overlapping fashion. *P < 0.001, signiﬁcantly different from NOD CD4
T-cell recipients (Kaplan-Meier log-rank analysis).
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revealed the retention of at least minimal pathogenic
activity. On the other hand, NOR T-cells are more suscep-
tible than those from NOD mice to activation-induced cell
death (AICD) (34). Therefore, abortive activation followed
by AICD may limit the effector function of NOR diabeto-
genic CD4 T-cells. Another nonmutually exclusive possi-
bility is that diabetogenic CD4 T-cells are more efﬁciently
suppressed in NOR than NOD mice. However, we found no
difference in the frequency or in vitro suppressive function
between NOD and NOR Tregs. These results suggested
that Treg function and the sensitivity of effector T-cells to
suppression are similar in NOD and NOR mice at the age
we tested. Our in vitro suppression assay did not consider
Treg antigenic speciﬁcity. -Cell antigen-speciﬁc Tregs are
superior than those with a diverse repertoire in blocking
type 1 diabetes development (35,36). Therefore, it is
possible that there is higher frequency of -cell–speciﬁc
Tregs in NOR than NOD mice, which in turn more effec-
tively suppress diabetogenic effectors in the former strain.
We previously demonstrated the NOR-derived Idd9/11
region conferred type 1 diabetes resistance at the B-cell
level (12). The current study found the same region also
controls the pathogenic activation of diabetogenic CD4
but not CD8 T-cells. B-cells are important APCs for
activating and expanding -cell–autoreactive CD4 T-cells in
NOD mice (37,38). However, it is unlikely that the diminished
diabetogenic activity of NOR and NOD.Chr4
NOR CD4 T-cells
is due to lower levels of disease-promoting B-cells than in
NOD mice. This argument is supported by the fact that CD4
T-cells from B-cell–deﬁcient NOD.IgH
null mice were as dia-
betogenic as those of NOD origin. Bone marrow chimerism
studies also indicated that intrinsic mechanisms were re-
sponsible for inducing tolerance in NOR and NOD.Chr4
NOR
CD4 T-cells. This indicates a NOR Idd9/11 region gene(s)
expressed in CD4 T-cells directly suppresses their diabeto-
genic potential.
A comparison of data depicted in Figs. 1A and 5
suggested that while not quite achieving statistical signif-
icance (P 
 0.06), CD4 T-cells from NOR mice may be
somewhat less diabetogenic than those from the
NOD.Chr4
NOR strain. Thus, although representing a pri-
mary contributor, the Idd9/11 locus may not be the sole
genetic element suppressing diabetogenic CD4 T-cell re-
sponses in NOR mice. In particular, although not suppres-
sive of diabetogenic CD4 T-cells by themselves, genes
within the Chr1 (Idd5.2, D1Mit532-D1Mit8) and/or Chr2
(Idd13, D2Mit63-D2Mit48) congenic intervals analyzed
here may interactively work with Idd9/11 region genes to
further inhibit the development or function of such patho-
genic effectors. Alternatively, other genetic regions distin-
guishing NOR from NOD mice that were not analyzed in
the current study may act independently or interactively
with a Idd9/11 region gene(s) to regulate the diabetogenic
activity of CD4 T-cells.
The type 1 diabetes–protective congenic interval in
NOD.Chr4
NOR mice does not contain the previously re-
ported Idd9.3 region (10,39). Therefore, the Idd9.3 candi-
date gene Cd137 cannot be a type 1 diabetes–protective
factor in NOR mice. Another difference between the type 1
diabetes protective Idd9 congenic interval originally re-
ported by Wicker and colleagues (40) and that present in
the NOD.Chr4
NOR stock is the donor strain. The type 1
diabetes–protective Idd9 congenic interval described by
Wicker and colleagues is derived from C57BL/10 (B10)
rather than NOR mice. In NOR mice, 12% of the genome
is derived from C57BLKS/J, which itself is composed of
genetic material mostly of B6 origin, but also from the
DBA/2J and possibly the B10 and 129 strains (41). The
Chr4 type 1 diabetes resistance region in NOR mice is
complex and contains both B6 and DBA/2J genetic mate-
rial (10). Therefore, it is possible that a DBA/2J-derived
genetic component(s) is responsible for NOD.Chr4
NOR
CD4 T-cells being less diabetogenic than those of NOD
origin. Although the B6 and B10 genomes are quite similar,
the distal region on Chr4 represents one region where they
differ (42). As a result, different allelic variants may
contribute to type 1 diabetes resistance in the B10-derived
Idd9 NOD congenic stock and the NOD.Chr4
NOR strain.
BDC2.5 T-cells represent a well-studied pancreatic
-cell autoreactive CD4 T-cell clone. However, BDC2.5
TCR transgenic NOD mice seldom develop type 1 diabetes
when other endogenous TCR molecules are also ex-
pressed (43). Type 1 diabetes resistance in NOD BDC2.5
transgenic mice is attributed to the presence of Tregs (44).
On the other hand, NY4.1 TCR transgenic CD4 T-cells
induce accelerated type 1 diabetes in NOD mice also
capable of expressing endogenously derived TCR mole-
cules (45). These collective ﬁndings indicate different
autoreactive CD4 T-cell clonotypes could be regulated by
distinct mechanisms, perhaps because of variations in
antigen speciﬁcity and TCR afﬁnity. Thus, it is signiﬁcant
that under conditions where they can express a full array
of TCR speciﬁcities, the development and/or function of
the diverse diabetogenic CD4 T-cell repertoire normally
generated in NOD mice is inhibited by the presence of a
NOR-derived Idd9/11 region gene(s). This NOR-derived
Idd9/11 gene(s) does not elicit increases in Treg numbers
or activity that keeps -cell autoreactive CD4 T-cells in
check, but rather, it functions intrinsically to suppress the
development or function of a broad range of such diabe-
togenic effectors. For this reason, the ultimate identiﬁca-
tion of the NOR-derived Idd9/11 region gene(s) capable of
directly suppressing development of a diverse repertoire
of -cell autoreactive CD4 T-cells could provide a target
for future type 1 diabetes prevention and/or reversal
therapies.
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FIG. 6. The diabetogenic activity of NOD and NOD.CD4
null CD8 T-cells
is comparable. Lethally irradiated NOD.CD8
null mice were injected
with 5  10
6 syngeneic bone marrow cells and 5  10
6 CD8 T-cells
puriﬁed from NOD mice or the NOD.Chr4
NOR congenic strain. Type 1
diabetes development was then analyzed weekly. The type 1 diabetes
incidence between NOD and NOD.Chr4
NOR CD8 T-cell recipient groups
is not signiﬁcantly different (Kaplan-Meier log-rank analysis).
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